Genetic variations in the metabolic enzymes CYP3A4, CYP3A5, CYP2D6, and CYP2C8 can significantly affect the pharmacokinetics of elagolix, potentially influencing its metabolism rate, blood levels, effectiveness, and risk of side effects. Additionally, genetic differences in transporter genes ABCB1 and SLCO1B1, which affect drug absorption and distribution, could modify the therapeutic outcomes and bioavailability of elagolix.